Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

32.45 -0.30 (-0.93%)
Streaming Delayed Price Updated: 12:29 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Castle Biosciences, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Advance Auto Parts, EPAM, and Castle Biosciences and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating EPAM, Castle, BeiGene and Fox and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology
From Castle Biosciences Inc.
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Comerica, Advance Auto Parts, EPAM, and Castle and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences Inc.
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Texas Capital, EPAM, and Castle and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Castle BioSciences, Inc. (CSTL)
From Kirby McInerney LLP
Via Business Wire
News headline image
CASTLE ALERT: Bragar Eagel & Squire, P.C. is Investigating Castle Biosciences, Inc. on Behalf of Castle Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Castle Biosciences Presents New Data Demonstrating the Ability of DecisionDx®-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging
From Castle Biosciences Inc.
Via Business Wire
News headline image
Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Castle Biosciences, Inc. (CSTL)
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Castle Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Castle Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Framework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational Dermatology
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting
From Castle Biosciences Inc.
Via Business Wire
News headline image
IDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Celebrates Skin Cancer Awareness Month
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Reports First Quarter 2023 Results
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event
From Castle Biosciences, Inc.
Via Business Wire
News headline image
DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients
From Castle Biosciences, Inc.
Via Business Wire
News headline image
TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort Study
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine
From Castle Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.